p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
- Citation:
- Urology vol 71 (5) 933-7
- Year:
- 2008
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 450
- Children:
- None
- Pharmas:
- Grants:
- CA03927, CA31946, CA32291, CA33601, CA41287, CA60138, CA77406, CA77651
- Corr. Author:
- Authors:
- Anthony V D'Amico Susan Halabi Robin Vollmer Marian Loffredo Elizabeth McMahon Ben Sanford Laura Archer Nicholas J Vogelzang Eric J Small Philip W Kantoff
- Networks:
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-159807, CALGB-9682
- Phases:
- 2, N/A
- Keywords:
- Adenocarcinoma, Aged, Aged, 80 and over, Flutamide, Gonadotropin-Releasing Hormone, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Prospective Studies, Prostatic Neoplasms, Risk Factors, Tumor Suppressor Protein p53